Shots:

• The companies collaborated to evaluate the safety & efficacy of NiKang’s NKT2152 (HIF2α inhibitor) + AVEO’s Fotivda (VEGFR TK inhibitor) in a P-II trial in patients with ccRCC who have not responded to or relapsed from prior therapies. The trial is expected to start in 2022
• NiKang will sponsor the trial & AVEO will co-fund the trial. The companies will form JDC to oversee the collaboration & will provide its drugs at no cost
• In preclinical/clinical data, the combination showed enhanced anti-tumor activity. Fotivda has been approved in the US, EU & other countries for advanced RCC while NKT2152 is currently in a P-I/II dose-escalation & expansion trial for the same indication

Ref: Businesswire | Image: Businesswire